AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · New Hampshire

HB1796

Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.

Status

Did not pass; died when the session ended

2026 Session

IntroducedDec 17, 2025 (done)
PassedDid not happen (skipped)
SignedDid not happen (skipped)
Law in effectDid not happen (skipped)

Sponsor: Michael Moffett (Republican)
Type: Therapeutic Access
Substances: Psilocybin

Official text

Summary (from PoliPsy)

Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: gc.nh.gov

Legislative history

February 3, 2026
Committee Report
February 3, 2026
Committee Report
February 3, 2026
In Committee
December 17, 2025
Referred
December 17, 2025
Introduced

Loading bill…